Noam Solomon

Noam Solomon, Co-founder and CEO of Immunai, is revolutionizing drug development by using AI to map the human immune system. He discusses the staggering costs and inefficiencies of drug discovery while sharing how Immunai's innovative approach could change the landscape of personalized therapies for diseases like cancer. Noam emphasizes the importance of a culture that embraces uncertainty, which drives their scientific innovation. He also highlights the collaboration between data science and biology, aiming to create tailored treatment solutions that could improve patient outcomes.